VISTAGEN THERAPEUTICS, INC. — Net Income by Fiscal Year
28 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/6b4f049e-45ea-482e-9a2a-c754fdd09f98/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-69.7M | 2025-04-01 – 2026-03-31 | evidence 0001628280-26-051404 |
| FY 2024 | $-51.4M | 2024-04-01 – 2025-03-31 | evidence 0001411685-25-000041 |
| FY 2023 | $-29.4M | 2023-04-01 – 2024-03-31 | evidence 0001411685-24-000022 |
| FY 2022 | $-59.2M | 2022-04-01 – 2023-03-31 | evidence 0001411685-24-000022 |
| FY 2021 | $-47.8M | 2021-04-01 – 2022-03-31 | evidence 0001851734-22-000349 |
| FY 2020 | $-17.9M | 2020-04-01 – 2021-03-31 | evidence 0001654954-21-007380 |
| FY 2019 | $-20.8M | 2019-04-01 – 2020-03-31 | evidence 0001654954-20-007107 |
| FY 2018 | $-24.6M | 2018-04-01 – 2019-03-31 | evidence 0001654954-19-007632 |
| FY 2017 | $-14.3M | 2017-04-01 – 2018-03-31 | evidence 0001654954-18-006990 |
| FY 2016 | $-10.3M | 2016-04-01 – 2017-03-31 | evidence 0001654954-17-005976 |
| FY 2015 | $-47.2M | 2015-04-01 – 2016-03-31 | evidence 0001415889-16-006331 |
| FY 2014 | $-13.9M | 2014-04-01 – 2015-03-31 | evidence 0001415889-15-002221 |
| FY 2013 | $-70.6M | 1998-11-26 – 2014-03-31 | evidence 0001415889-14-001957 |
| FY 2012 | $-12.9M | 2012-04-01 – 2013-03-31 | evidence 0001415889-13-001409 |
| FY 2011 | $-12.2M | 2011-04-01 – 2012-03-31 | evidence 0001415889-12-000973 |
| FY 2010 | $-42.7M | 1998-05-27 – 2011-03-31 | evidence 0001415889-14-001957 |
| FY 2009 | $-4.1M | 2009-04-01 – 2010-03-31 | evidence 0001415889-12-000973 |
| FY 2008 | $-4.7M | 2008-04-01 – 2009-03-31 | evidence 0001415889-12-000973 |
| FY 2007 | $-5.4M | 2007-04-01 – 2008-03-31 | evidence 0001415889-12-000973 |
| FY 2006 | $-2.0M | 2006-04-01 – 2007-03-31 | evidence 0001415889-12-000973 |
| FY 2005 | $-1.8M | 2005-04-01 – 2006-03-31 | evidence 0001415889-12-000973 |
| FY 2004 | $-1.1M | 2004-04-01 – 2005-03-31 | evidence 0001415889-12-000973 |
| FY 2003 | $-8.8M | 2003-04-01 – 2004-03-31 | evidence 0001415889-12-000973 |
| FY 2002 | $-502.6k | 2002-04-01 – 2003-03-31 | evidence 0001415889-12-000973 |
| FY 2001 | $-2.1M | 2001-04-01 – 2002-03-31 | evidence 0001415889-12-000973 |
| FY 2000 | $-1.8M | 2000-04-01 – 2001-03-31 | evidence 0001415889-12-000973 |
| FY 1999 | $-700.0k | 1999-04-01 – 2000-03-31 | evidence 0001415889-12-000973 |
| FY 1998 | $-230.9k | 1998-05-26 – 1999-03-31 | evidence 0001415889-12-000973 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
VISTAGEN THERAPEUTICS, INC. — all facts · Revenue · Operating Income